不可手术切除的肝转移癌行50Gy/10f分割模式立体定向放疗疗效评估

卢振国; 孙君碟; 向作林; 卢欣; 王爱华; 袁骏

doi:10.12025/j.issn.1008-6358.2020.20200254

不可手术切除的肝转移癌行50Gy/10f分割模式立体定向放疗疗效评估

Stereotactic body radiotherapy with 50 Gy in 10 fractions for unresectable liver metastasis

摘要

摘要:
目的探讨立体定向放疗（stereotactic body radiotherapy，SBRT）对不可手术切除的肝转移癌患者的临床疗效。
方法回顾性分析2018年3月至2019年11月同济大学附属东方医院收治的28例肝转移癌患者的临床资料。予4D-CT或呼吸门控技术进行CT模拟定位，予肝转移病灶50Gy/10f的剂量分割模式。
结果所有患者均顺利完成全程放疗。半年和1年的总生存率（overall survival，OS）为95.0%和70.1%。1年的局部控制率（local control，LC）为92.2%。常见的不良反应为Ⅰ~Ⅱ级的恶心、纳差、腹痛等，无Ⅲ级以上的不良反应发生。
结论以50Gy/10f分割模式的立体定向放射治疗技术治疗肝转移癌安全有效。

Abstract:
Objective To explore the clinical efficacy of stereotactic body radiotherapy (SBRT) for the treatment of patients with unresectable liver metastasis.
Methods Data of 28 patients with unresectable liver metastases were retrospectively analyzed. All patients were admitted to the Shanghai East Hospital from March 2018 to November 2019. Patients underwent 4D-CT or respiration gating for CT simulation. The prescription dose for the liver metastasis was 50 Gy in 10 fractions.
Results All patients successfully completed the SBRT treatment. The median overall survival was 7.4 months. The six months and one-year survival rates were 95.0% and 70.1%, respectively. The local control rate for one year was 92.2%. The most common toxicity was grade Ⅰ or Ⅱ nausea, poor appetite, and abdominal pain. No grade Ⅲ or worse toxicity was found.
Conclusions SBRT with 50 Gy in 10 fractions is a safe and effective treatment for patients with unresectable liver metastasis.

HTML全文

参考文献(20)

施引文献

资源附件(0)